Diabetic Nephropathy Market

Global Market Study on Diabetic Nephropathy: Asia to Witness Highest Growth by 2020

Diabetic Nephropathy Market Segmented By Angiotensin-Converting Enzyme Inhibitors, Diuretics, Calcium Channel Blockers, Renin Inhibitors, Connective Tissue Growth Factor Inhibitors, Antioxidant Inflammation Modulator, Monocyte Chemoattractant Proteins Inhibitor, Endothelin-A Receptor Antagonist

  • January-2015
  • PMRREP3594
  • 106 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Table of Content

 

Chapter 1 Preface

1.1 Report Description

1.2 Research Methodology

1.3 Assumptions

 

Chapter 2 Market Synopsis

 

Chapter 3 Porter’s Five Forces Analysis

3.1 Bargaining Power of Suppliers

3.2 Bargaining Power of Buyers

3.3 Threat of New Entrants

3.4 Threat of Substitutes

3.5 Intensity of Rivalry

 

Chapter 4 Industry Overview

4.1 Market Definition

4.2 Market Drivers

     4.2.1 Increasing prevalence of diabetes

     4.2.2 Globally rising obesity increasing the prevalence of diabetes

     4.2.3 Increasing R&D investments in drug discovery and development

     4.2.4 Rising awareness among people about diabetes and kidney-related disorders

4.3 Impact Analysis of Market Drivers

4.4 Market Restraints

     4.4.1 Strict regulatory requirements and long approval time for drugs

     4.4.2 Lack of comprehensive therapeutic management for diabetic nephropathy

4.5 Impact Analysis of Market Restraints

4.6 Market Trends

     4.6.1 Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market

 

Chapter 5 Global Market Size and Forecast

 

Chapter 6 Market Size and Forecast by Mode of Treatment

6.1 Disease Modifying Therapies

     6.1.1 Angiotensin-Converting Enzyme Inhibitors

     6.1.2 Angiotensin Receptor Blockers

     6.1.3 Diuretics

     6.1.4 Calcium Channel Blockers

     6.1.5 Renin Inhibitors

     6.1.6 Connective Tissue Growth Factor Inhibitors

     6.1.7 Antioxidant Inflammation Modulator

     6.1.8 Monocyte Chemoattractant Proteins Inhibitor

     6.1.9 Endothelin-A Receptor Antagonist

     6.1.10 G Protein-Coupled Receptors

 

Chapter 7 Market Size and Forecast by Geography

7.1 North America

     7.1.1 Scenario in the U.S.

     7.1.2 Scenario in Canada

7.2 Europe

     7.2.1 Scenario in Germany

     7.2.2 Scenario in France

     7.2.3 Scenario in the U.K.

7.3 Asia

     7.3.1 Scenario in Japan

     7.3.2 Scenario in China

     7.3.3 Scenario in India

 

Chapter 8 Pipeline Drugs for Diabetic Nephropathy

8.1 Drugs Under Development for Diabetic Nephropathy

 

Chapter 9 Competitive Scenario

9.1 Competitive Benchmarking

 

Chapter 10 Company Profiles

10.1 Novartis AG

     10.1.1 Company overview

     10.1.2 Products and services

     10.1.3 Financial performance

     10.1.4 Key developments

10.2 Merck & Co., Inc.

     10.2.1 Company overview

     10.2.2 Products and services

     10.2.3 Financial performance

     10.2.4 Key developments

10.3 Pfizer, Inc.

     10.3.1 Company overview

     10.3.2 Products and services

     10.3.3 Financial performance

     10.3.4 Key developments

10.4 Abbott Laboratories

     10.4.1 Company overview

     10.4.2 Products and services

     10.4.3 Financial performance

     10.4.4 Key developments

10.5 Sanofi

     10.5.1 Company overview

     10.5.2 Products and services

     10.5.3 Financial performance

     10.5.4 Key developments

10.6 Eli Lilly and Company

     10.6.1 Company overview

     10.6.2 Products and segments

     10.6.3 Financial performance

     10.6.4 Key developments

10.7 Reata Pharmaceuticals, Inc.

     10.7.1 Company overview

     10.7.2 Products and segments

     10.7.3 Financial performance

     10.7.4 Key developments

10.8 Bayer AG

     10.8.1 Company overview

     10.8.2 Products and segments

     10.8.3 Financial performance

     10.8.4 Key developments

10.9 AbbVie, Inc.

     10.9.1 Company overview

     10.9.2 Products and segments

     10.9.3 Financial performance

     10.9.4 Key developments

10.10 Mitsubishi Tanabe Pharma Corporation

     10.10.1 Company overview

     10.10.2 Products and segments

     10.10.3 Financial performance

     10.10.4 Key developments

Find Out More about the Report Coverage

List of Tables

List of Tables

 

TABLE 1 Market Snapshot: Diabetic nephropathy market, 2014 and 2020

TABLE 2 Drivers for diabetic nephropathy market: Impact analysis

TABLE 3 Estimated average timelines for clinical trial approval in various countries

TABLE 4 Restraints for diabetic nephropathy market: Impact analysis

TABLE 5 Global diabetic nephropathy market size, by region, 2010 – 2013 (USD thousand)

TABLE 6 Global diabetic nephropathy market size, by region, 2014 – 2020 (USD thousand)

TABLE 7 Global diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 8 Global diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 9 Global DMT market size, by region, 2010 – 2013 (USD thousand)

TABLE 10 Global DMT market size, by region, 2014 – 2020 (USD thousand)

TABLE 11 Global DMT market size, by drug categories, 2010 – 2013 (USD thousand)

TABLE 12 Global DMT market size, by drug categories, 2014 – 2020 (USD thousand)

TABLE 13 Global ACE inhibitors market size, by region, 2010 – 2013 (USD thousand)

TABLE 14 Global ACE inhibitors market size, by region, 2014 – 2020 (USD thousand)

TABLE 15 Global ARBs market size, by region, 2010 – 2013 (USD thousand)

TABLE 16 Global ARBs market size, by region, 2014 – 2020 (USD thousand)

TABLE 17 Global diuretics market size, by region, 2010 – 2013 (USD thousand)

TABLE 18 Global diuretics market size, by region, 2014 – 2020 (USD thousand)

TABLE 19 Global CCBs market size, by region, 2010 – 2013 (USD thousand)

TABLE 20 Global CCBs market size, by region, 2014 – 2020 (USD thousand)

TABLE 21 Global renin inhibitors market size, by region, 2010 – 2013 (USD thousand)

TABLE 22 Global renin inhibitors market size, by region, 2014 – 2020 (USD thousand)

TABLE 23 Global CTGF inhibitors market size, by region, 2010 – 2013 (USD thousand)

TABLE 24 Global CTGF inhibitors market size, by region, 2014 – 2020 (USD thousand)

TABLE 25 Global AIM market size, by region, 2010 – 2013 (USD thousand)

TABLE 26 Global AIM market size, by region, 2014 – 2020 (USD thousand)

TABLE 27 Global MCP inhibitors market size, by region, 2010 – 2013 (USD thousand)

TABLE 28 Global MCP inhibitors market size, by region, 2014 – 2020 (USD thousand)

TABLE 29 Global ETAR market size, by region, 2010 – 2013 (USD thousand)

TABLE 30 Global ETAR market size, by region, 2014 – 2020 (USD thousand)

TABLE 31 Global GPCRs market size, by region, 2010 – 2013 (USD thousand)

TABLE 32 Global GPCRs market size, by region, 2014 – 2020 (USD thousand)

TABLE 33 The North American diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand)

TABLE 34 The North American diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand)

TABLE 35 The U.S. diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 36 The U.S. diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 37 The Canadian diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 38 The Canadian diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 39 The European diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand)

TABLE 40 The European diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand)

TABLE 41 The German diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 42 The German diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 43 The French diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 44 The French diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 45 The U.K. diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 46 The U.K. diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 47 The Asian diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand)

TABLE 48 The Asian diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand)

TABLE 49 The Japanese diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 50 The Japanese diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 51 The Chinese diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 52 The Chinese diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 53 The Indian diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 54 The Indian diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 55 Major pipeline drugs for diabetic nephropathy

TABLE 56 Product categories of Novartis AG

TABLE 57 Product categories of Merck & Co., Inc.

TABLE 58 Product categories of Pfizer, Inc.

TABLE 59 Product categories of Abbott Laboratories

TABLE 60 Product categories of Sanofi

TABLE 61 Product segments of Eli Lilly and Company

TABLE 62 Product categories of Reata Pharmaceuticals, Inc.

TABLE 63 Product categories of Bayer AG

TABLE 64 Product categories of AbbVie, Inc.

TABLE 65 Product categories of Mitsubishi Tanabe Pharma Corporation

Explore Persistence Market Research’s expertise in promulgation of the business !

List of Chart

List of Figures 

 

FIG. 1 Diabetic nephropathy market: Porter’s five forces analysis

FIG. 2 Major DMT for diabetic nephropathy

FIG. 3 Number of people with diabetes mellitus (20 – 79 years) in major countries, 2010, and 2030 (million)

FIG. 4 Prevalence of overweight and obese males aged 30 years and above, 2005 and 2015 (%)

FIG. 5 Prevalence of overweight and obese females aged 30 years and above, 2005 and 2015 (%)

FIG. 6 Global diabetic nephropathy market share, by region, by value, 2013

FIG. 7 Global diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 8 Global DMT market share, by region, by value, 2013 30

FIG. 9 Global DMT market share, by disease categories, by value, 2013

FIG. 10 Global ACE inhibitors market share, by region, by value, 2013

FIG. 11 Global ARBs market share, by region, by value, 2013

FIG. 12 Global diuretics market share, by region, by value, 2013

FIG. 13 Global CCBs market share, by region, by value, 2013

FIG. 14 Global renin inhibitors market share, by region, by value, 2013

FIG. 15 Global CTGF inhibitors market share, by region, by value, 2013

FIG. 16 Global AIM market share, by region, by value, 2013

FIG. 17 Global MCP inhibitors market share, by region, by value, 2013

FIG. 18 Global ETAR market share, by region, by value, 2013

FIG. 19 Global GPCRs market share, by region, by value, 2013

FIG. 20 The North American diabetic nephropathy market share, by country, by value, 2013

FIG. 21 The U.S. diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 22 The Canadian diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 23 The European diabetic nephropathy market share, by country, by value, 2013

FIG. 24 The German diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 25 The French diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 26 The U.K. diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 27 The Asian diabetic nephropathy market share, by country, by value, 2013

FIG. 28 The Japanese diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 29 The Chinese diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 30 The Indian diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 31 Competitive landscape of diabetic nephropathy market, 2013

FIG. 32 Novartis AG’s net sales and net income, 2011 – 2013 (USD million)

FIG. 33 Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million)

FIG. 34 Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million)

FIG. 35 Abbott Laboratories’ net sales and net earnings, 2011 – 2013 (USD million)

FIG. 36 Sanofi’s net sales and net income, 2011 – 2013 (USD million)

FIG. 37 Eli Lilly and Company’s revenue and net income, 2011 – 2013 (USD million)

FIG. 38 Bayer AG’s net sales and net income, 2011 – 2013 (USD million)

FIG. 39 AbbVie, Inc.’s net sales and net earnings, 2011 – 2013 (USD million)

FIG. 40 Mitsubishi Tanabe Pharma Corporation’s net sales and net earnings, 2011 – 2013 (USD million)

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Description

Diabetes is a disease characterized by high blood sugar level which is caused by improper functioning of the pancreas, the organ secreting insulin in the body. Diabetic nephropathy is a disease of the kidney glomerulus and happens to be one of the most significant complications in terms of mortality and morbidity for patients with diabetes. The disease is mainly characterized by macroalbuminuria, where in a single day presence of albumin in the urine increases over 300 milligrams. In addition, diabetic nephropathy is also caused by proteinuria, imbalanced glomerular filtration rate, and hypertension. The imbalanced glomerular filtration rate of the kidney builds up waste products in the blood and increases the level of protein in the urine. Signs and symptoms of diabetic nephropathy are unknown in early stage of the disease. However, major signs and symptoms of diabetic nephropathy in its later stages are increased albumin secretion in urine, high blood pressure, ankle and leg swelling, high level of blood urea nitrogen (BUN) and serum creatinine, itching, morning weakness, nausea, vomiting, and anemia. Disease modifying therapies (DMT) that employ angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used in the treatment of diabetic nephropathy. ACE inhibitors, such as enalapril, captopril, ramipril, and lisinopril, lower the amount of protein in the urine. ARBs and ACE inhibitors together provide greater protection to the kidney than they individually can. Major ARBs are candesartan, losartan and irbesartan.

 

Growing prevalence of diabetes and obesity, increasing R&D investments in drug discovery and development, and rising awareness about diabetes and kidney-related disorders are some of the major drivers of the diabetic nephropathy market. On the other hand, stringent regulatory requirements and longer approval time for drugs as well as a lack of comprehensive therapeutic management for diabetic nephropathy are major concerns for the market. Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market is the recent market trends that have been observed in diabetic nephropathy market.

 

North America has the largest market for diabetic nephropathy, followed by Europe. Some of the fastest growing markets for diabetic nephropathy are China and Japan. This is due to increase in the diabetic population and rise in incidence rates of various kidney diseases in these countries.

 

This report provides in-depth analysis and estimation of the diabetic nephropathy market for the period 2014 to 2020, considering 2013 as the base year for calculation. In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report. The diabetic nephropathy market is categorized on the basis of mode of treatment and geography. Based on a mode of treatment for diabetic nephropathy, the market comprises DMT. DMT is further categorised into ACE inhibitors, ARBs, diuretics, calcium channel blockers (CCBs), renin inhibitors, connective tissue growth factor (CTGF) inhibitors, antioxidant inflammation modulators (AIMs), monocyte chemoattractant protein (MCP) inhibitors, endothelin-A receptor (ETAR) antagonist, G protein-coupled receptors (GPCRs), and others. On the basis of geography, the report identifies and analyses the market size and predictions for North America, Europe, Asia, and Rest of the World (RoW). 

 

 

Recommendations

Emea Dearomatic Solvents Market

Global De-aromatic solvents market is expected to register a CAGR of 5.0% over the forecast period (2016 – 2024), to reach valuation of US$ 556.0 Mn by 2024.

White Spirit Market

White Spirits Market are of four types - Type 1, Type 2, Type 3, and Type 0, which are categorized on their aromatic content basis. White spirits are consumed in a wide range of applications such as paint thinners, cleaning solvents, degreasing solvents, fuels, and disinfectants, among others..

Isoparaffin Solvents Market

The incremental $ opportunity created by the market during the forecast period is pegged at nearly US$ 51.9 Mn. The isoparaffin solvents market is expected to expand at a CAGR of 3.7% during the forecast period..

Propylene Glycol Ether Market

The global propylene glycol ether market is estimated to have been valued at US$ 1,604.1 Mn by 2017 end and is expected to reach US$ 2,088.4 Mn by the end of 2026 while expanding at a CAGR of 3.0% over the forecast period. .

Our Clients

Our Clients